Data used to design this calculator were extracted from an independent study that has been presented at the AACR24 (1) and AMP24 (2) and which highlights the fact that “OncoDEEP Kit’s mean coverage of the samples is more uniform thereby allowing to pool 2- to 3-times more samples per seq run.” The calculator assumes that the sample quality is good. OncoDNA acknowledges that poor sample quality can lead to suboptimal data and may require a detailed analysis of the raw data.
These estimations are approximate, derived from reagents from extracted DNA to ready-to-sequence captures, flow cell, data analysis and interpretation expenses alone. The use of lab equipment or general lab reagents needed is not taken into account We recommend users conduct their assessments before finalizing any procurement decisions. For further assistance, please reach out to OncoDNA’s sales team.
* Please note that the competitor placeholder values mentioned above represent published list prices of the Illumina TSO500 kit consumables, BioIT process and interpretation software. Third-party trademarks mentioned belong to their respective owners and are utilized here solely for identification purposes, with no implication of endorsement.
** As demonstrated in a recent study (1), the exceptional coverage uniformity OncoDEEP® Kits allows to sequence more samples on the same budget without sacrificing the quality of result at all. Having eliminated the need to over sequence, OncoDEEP® Kits allow users to pool more samples on the sequencing platform, ultimately leading to cost reduction. It has been reported that OncoDEEP® DNA Kit supports the pooling of at least 3X more samples when compared to TSO500.
(▲) Secondary analysis cost calculation model: Licence fee per year: 25.583€ / (24 * 30) (Quantity of samples per week: 24 * number of sequencing weeks)
(1) Comprehensive Genomic Profiling of solid tumor patients with the OncoDEEP assay for broad analysis in clinical diagnostics, Hendrikus Jan Dubbink, et al. (AACR 2024)
(2) Comprehensive Genomic Profiling of solid tumor patients with the OncoDEEP assay for broad analysis in clinical diagnostics, Froyen, et al.(AMP 2024)
